A Study in Healthy Japanese Young Adults to Assess the Safety, Tolerability, and Immunogenicity of HEPTAVAX-II Manufactured Using a Modified Process.

Trial Profile

A Study in Healthy Japanese Young Adults to Assess the Safety, Tolerability, and Immunogenicity of HEPTAVAX-II Manufactured Using a Modified Process.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Hepatitis B vaccine recombinant (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 Dec 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top